Executive Summary
A high-severity privilege escalation vulnerability (CVE-2026-21997, CVSS 8.5) has been disclosed in the Common Core component of Oracle Life Sciences Empirica Signal versions 9.2.1 through 9.2.3. The flaw allows a low-privileged, authenticated attacker with network access via HTTP to compromise the confidentiality and integrity of the Empirica Signal pharmacovigilance platform.
CVSS Score: 8.5 (High)
Published to the NVD on April 21, 2026, this vulnerability falls within Oracle's April 2026 Critical Patch Update (CPU) cycle. Organizations running affected versions of Empirica Signal — a drug safety signal detection and management platform used by pharmaceutical companies and regulatory bodies — should prioritize immediate remediation.
Vulnerability Overview
| Attribute | Value |
|---|---|
| CVE ID | CVE-2026-21997 |
| CVSS Score | 8.5 (High) |
| Product | Oracle Life Sciences Empirica Signal |
| Component | Common Core |
| Affected Versions | 9.2.1, 9.2.2, 9.2.3 |
| Attack Vector | Network |
| Attack Complexity | Low |
| Privileges Required | Low |
| User Interaction | None |
| Published | 2026-04-21 |
Affected Products
| Vendor | Product | Affected Versions | Fix Available |
|---|---|---|---|
| Oracle | Life Sciences Empirica Signal (Common Core) | 9.2.1, 9.2.2, 9.2.3 | April 2026 CPU |
Vulnerability Details
Common Core Component Flaw
CVE-2026-21997 resides in the Common Core component of Oracle Life Sciences Empirica Signal. Oracle describes this as an "Easily exploitable" vulnerability, meaning a low-privileged attacker with existing network access can reliably exploit the flaw without special conditions.
The vulnerability allows an attacker who already holds a low-privilege account within the application to escalate their access and compromise confidentiality and integrity of data managed by the platform. This is particularly significant in the context of Empirica Signal, which is used to detect, track, and manage drug safety signals — data that is highly sensitive in regulated pharmaceutical and healthcare environments.
Attack prerequisites:
- Network access to the Empirica Signal instance via HTTP
- Low-privileged user account in the application
- No additional user interaction required
Why This Matters for Life Sciences Organizations
Oracle Empirica Signal is widely deployed at:
- Pharmaceutical manufacturers managing post-market drug safety obligations
- Contract research organizations (CROs) performing pharmacovigilance on behalf of drug sponsors
- Regulatory agencies and health authorities tracking adverse event signals
A successful exploit could allow a malicious insider or a low-privileged attacker who has compromised a basic account to:
| Impact | Description |
|---|---|
| Data access | Read pharmacovigilance case data, signal assessments, and regulatory submissions |
| Integrity compromise | Modify signal detection configurations or assessment outcomes |
| Regulatory risk | Tamper with data supporting regulatory filings or signal management decisions |
| Insider threat amplification | Low-trust roles elevated beyond intended authorization boundaries |
Deployment Context and Risk
| Deployment Context | Risk Level | Notes |
|---|---|---|
| Internet-exposed Empirica Signal | High | Low-privilege exploit from any authenticated network user |
| Internal deployment with shared accounts | High | Any user with basic login can escalate access |
| Regulatory submission environment | Critical | Data integrity for pharmacovigilance filings at risk |
| Multi-tenant CRO deployments | High | Cross-tenant data exposure possible if access controls are bypassed |
Organizations using Empirica Signal for 21 CFR Part 11 or EU GVP pharmacovigilance compliance should consider this a priority remediation given the regulatory implications of data integrity compromise.
Recommended Mitigations
1. Apply the April 2026 Oracle CPU Patch
Oracle released a patch for CVE-2026-21997 as part of the April 2026 Critical Patch Update. Apply the patch immediately.
# Verify current Empirica Signal version
# Check Oracle MOS (My Oracle Support) for patch availability
# CPU Advisory: oracle.com/security-alerts/cpuapr2026.html2. Restrict Network Access
While patching is in progress, limit access to the Empirica Signal application:
# Block HTTP access from untrusted networks
# Allow only from authorized workstations and subnets
# Example firewall rule (adjust port and interface as needed)
iptables -I INPUT -p tcp --dport 443 -s <AUTHORIZED_SUBNET> -j ACCEPT
iptables -I INPUT -p tcp --dport 443 -j DROP3. Audit User Accounts and Permissions
Review all low-privileged accounts to identify any unauthorized access escalation:
- Audit Empirica Signal user roles and permissions
- Identify accounts with minimal legitimate need and disable or restrict
- Review audit logs for unusual access patterns or configuration changes
- Check for recent changes to signal detection configurations or assessments
4. Monitor for Exploitation Indicators
| Indicator | Description |
|---|---|
| Unexpected configuration changes in Empirica Signal | Possible integrity compromise |
| Low-privilege accounts accessing high-sensitivity data | Privilege escalation attempt |
| Unusual API calls to Common Core endpoints | Exploitation probe |
| Unauthorized export of signal data or reports | Data exfiltration |
5. Assess Regulatory Impact
If exploitation is suspected:
- Preserve audit logs — Oracle Empirica Signal maintains detailed audit trails; preserve these immediately
- Notify compliance/quality team — Potential data integrity issues in a regulated environment require documented investigation
- Review recent signal assessments — Check for unauthorized modifications to pharmacovigilance data
- Contact Oracle Support — Engage Oracle Life Sciences support for incident guidance
Post-Remediation Checklist
- Apply Oracle April 2026 CPU patch — verify installation and system stability
- Review audit logs — inspect for access anomalies in the 30 days prior to patching
- Validate data integrity — confirm no unauthorized modifications to signal data or assessments
- Update access controls — apply least-privilege to all Empirica Signal user accounts
- Re-assess network segmentation — ensure Empirica Signal is not internet-accessible without strong authentication
- Document remediation — record patching and investigation for regulatory compliance records
References
- CVE-2026-21997 — NVD
- Oracle April 2026 Critical Patch Update
- Oracle Life Sciences Empirica Signal Product Page